Patent SG-11201906427Q-A (SG)
Title: Heterocyclic spiro compounds as magl inhibitors
Inventor: BRODNEY MICHAEL AARON
IPC: C07D401/12
Filed: 2018-01-09
Abstract: International Patent Classification: CO7D 471/10 (2006.01) A61P 3/00 (2006.01) CO7D 493/10 (2006.01) A61P 25/00 (2006.01) CO7D 498/10 (2006.01) A61P 37/00 (2006.01) CO7D 401/12 (2006.01) A61K 31/438 (2006.01) (21) International Application Number: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT omit VIII °nolo o1111 1111101 ow (10) International Publication Number WO 2018/134698 Al PCT/IB2018/050128 (22) International Filing Date: 09 January 2018 (09.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/449,242 23 January 2017 (23.01.2017) US (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US). (72) Inventors: BRODNEY, Michael Aaron; 100 Upland Avenue, Newton, Massachusetts 02461 (US). BUTLER, Christopher Ryan; 121 Spring Lane, Canton, Massachu- setts 02021 (US). HELAL, Christopher John; 18 Elm Street, Mystic, Connecticut 06355 (US). MCALLISTER, Laura Ann; 428 Massachusetts Ave., Apt. 6, Arlington, Massachusetts 02474 (US). O'NEIL, Steven Victor; 42 Ar- bor Crossing, East Lyme, Connecticut 06333 (US). VER- HOEST, Patrick Robert; 23 Calvin Road, Newton, Con- necticut 02460 (US). (74) Agent: WALDRON, Roy; PFIZER INC., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) = (54) Title: HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS (57) : The present invention provides, in part, heterocyclic spiro com- O pounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions con- taining such compounds or salts, and their uses for treating MAGL-mediated dis- eases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer. W O 20 18/ 13 4698 Al